durvalumab,tremelimumab,sorafenib
astrazeneca,bayer
[]
the #oncoalerttoptweet for day1 #gi23 tweet the stride t300 d regimen or the himalaya regimen in hcc studied in dmmr/msi-high #ctdna &amp; pathologic complete response as endpoints. a small #chalabiplot best, 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨